Weekly somapacitan is effective and well-tolerated in children born small for gestational age: randomized phase 3 trial
Agnès Linglart1; Volker Böttcher2; Michael Højby3; Carlos Alberto Longui4; Joshua Smith5; Masanobu Kawai6
MATERIALS AVAILABLE
Slide
14:15 - 14:45
CEST
RC6.3
ORAL PRESENTATION
Weekly somapacitan is effective and well-tolerated in children with idiopathic short stature: randomized phase 3 trial
Jennifer Abuzzahab1; Andrew Dauber2; Michael Højby3; Haruo Mizuno4; Philip Murray5, 6; Moshe Phillip7, 8; Tadej Battelino9
MATERIALS AVAILABLE
Slide
16:55 - 17:55
CEST
P633
POSTER
MySoConnect® for Sogroya®: long-acting growth hormone for patients with growth-related disorders and their caregivers
Primož Kotnik1; Barbara Murn Berkopec1; Tadej Battelino1; Sandhya Gopalakrishnan2; Sönke Johannsen3; Liam Mc Morrow4; Klemen Dovč1
MATERIALS AVAILABLE
Poster
16:55 - 17:55
CEST
P635
POSTER
Evaluation of features for a digital application for growth hormone therapy using perceptions gathered from patients, caregivers and healthcare professionals
Efficacy and safety of somapacitan versus daily growth hormone at 52 weeks in patients with growth hormone deficiency: pooled analysis of the randomised REAL 3, REAL 4 and REAL 6 clinical trials
Lars Sävendahl1; Aristides Maniatis2; Martin Wabitsch3; Alberto Pietropoli4; Nicky Kelepouris5; Michael Højby6; Junfen Fu7; Jun Mori8; Bradley S. Miller9
MATERIALS AVAILABLE
Poster
16:55 - 17:55
CEST
RC14.1a
POSTER
Long-term efficacy and safety of once-weekly somapacitan in children with growth hormone deficiency: 7-year results from the randomised REAL 3 trial
Lars Sävendahl1; Tadej Battelino2; Michael Højby3; Tina Leunbach3; Paul Saenger4; Lawrence Silverman5; Reiko Horikawa6
MATERIALS AVAILABLE
Poster
16:55 - 17:55
CEST
LB196
POSTER
Growth hormone therapy demonstrates no significant impact on thyroid function in children with growth hormone deficiency
Agnes Linglart1; Tejasweeni Rajput2; Iris Guttmark Little3; Masanobu Kawai4; Michael Højby Rasmussen5; Tina Lund Leunbach5
MATERIALS AVAILABLE
Poster
16:55 - 17:55
CEST
LB92
POSTER
Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children born small for gestational age or with idiopathic short stature or noonan syndrome
Julie Desrochers1; Philippe Backeljauw2; Michael Højby1; Agnès Linglart3; Jun Mori4; Rory Leisegang1
MATERIALS AVAILABLE
Poster
16:55 - 17:55
CEST
RC6.4a
POSTER
Weekly somapacitan is effective and well-tolerated in children born small for gestational age: randomized phase 3 trial
Agnès Linglart1; Volker Böttcher2; Michael Højby3; Carlos Alberto Longui4; Joshua Smith5; Masanobu Kawai6
MATERIALS AVAILABLE
Poster
16:55 - 17:55
CEST
RC6.3a
POSTER
Weekly somapacitan is effective and well-tolerated in children with idiopathic short stature: randomized phase 3 trial
Jennifer Abuzzahab1; Andrew Dauber2; Michael Højby3; Haruo Mizuno4; Philip Murray5, 6; Moshe Phillip7, 8; Tadej Battelino9
MATERIALS AVAILABLE
Poster
16:55 - 17:55
CEST
LB91
POSTER
Weekly somapacitan is effective and well-tolerated in children with noonan syndrome: randomized phase 3 trial
Alexander A. L. Jorge1; Assunta Albanese2; Michael Højby3; Kamil Soltysik3; Thomas Edouard4,5; Anna Grandone6; Michael Tansey7; Jun Mori8
MATERIALS AVAILABLE
Poster
Monday, 12 May 2025
13:00 - 14:30
CEST
Symposium
Managing obesity: A lifelong perspective from childhood to adulthood
Mikael Rydén; Antje Körner; Megha Poddar; Morten Bøttcher
MATERIALS AVAILABLE
Teaser Video
Tuesday, 13 May 2025
13:45 - 14:15
CEST
RC14.1
ORAL PRESENTATION
Long-term efficacy and safety of once-weekly somapacitan in children with growth hormone deficiency: 7-year results from the randomised REAL 3 trial
Lars Sävendahl1; Tadej Battelino2; Michael Højby3; Tina Leunbach3; Paul Saenger4; Lawrence Silverman5; Reiko Horikawa6